Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;15(1):909-913.
doi: 10.3892/etm.2017.5451. Epub 2017 Nov 6.

Effects of telmisartan on vascular endothelial function, inflammation and insulin resistance in patients with coronary heart disease and diabetes mellitus

Tao Chen  1 , Jieyong Xing  1 , Yanshao Liu  1
Affiliations

Effects of telmisartan on vascular endothelial function, inflammation and insulin resistance in patients with coronary heart disease and diabetes mellitus

Tao Chen et al. Exp Ther Med. 2018 Jan.

Abstract

The aim of the present study was to investigate the effects of telmisartan on vascular endothelial functions, inflammatory factors and insulin resistance of coronary heart disease patients complicated with diabetes mellitus. In total, 80 coronary heart disease patients complicated with type 2 diabetes mellitus, admitted and treated in the Zhangqiu Hospital from January 2016 to March 2017 were enrolled in the study. Each patient was randomly assigned to an observation (n=40) or a control group (n=40) using a random number table. Conventional symptomatic and supporting therapies were administered to all the patients in the two groups for 12 consecutive weeks, while additional telmisartan was given only to patients in the observation group. Markers of glucose metabolism, vascular endothelial function and inflammation were determined before and after intervention, to compare averages between groups. Results showed the levels of fasting blood glucose and blood glucose in the observation group were significantly lower than those in the control group (p<0.05) after 4 weeks of treatment. The levels of HOMA-IR in the observation group were clearly improved compared to those in the control group during the same period (p<0.05). After the intervention, the levels of FINS and HOMA-IR in the observation group improved significantly more compared with those in the control group (p<0.05), while the levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and C-reactive protein (CRP) were much lower than those in the control group (p<0.05). Furthermore, at the 4th, 8th and 12th week after starting the treatment, the vascular endothelin (ET) levels in the observation group were significantly lower than those in the control group (p<0.05). In addition, the brachial artery diameters in the basal state were significantly larger than those in the control group (p<0.05) for the same time-points. Coronary heart disease patients complicated with diabetes mellitus whose treatment includes telmisartan can better regulate their blood glucose, reduce the insulin resistance and body inflammatory responses and improve their vascular endothelial functions.

Keywords: coronary heart disease; diabetes mellitus; inflammatory factor; insulin resistance; telmisartan; vascular endothelial function.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Changing trends of fasting blood glucose in the two groups in the intervention process.
Figure 2.
Figure 2.
Comparison of trends of HOMA-IR values during the intervention process in the two groups. HOMA-IR, homeostasis model assessment of insulin resistance.
Figure 3.
Figure 3.
Comparisons of ET changes in the two groups at different time-points of intervention. ET, endothelin.
Figure 4.
Figure 4.
Comparisons of average values of brachial artery diameters in the basal state in two groups during the intervention process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Park S, Kario K, Park CG, Huang QF, Cheng HM, Hoshide S, Wang JG, Chen CH, Characteristics On the ManagEment of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG) Target blood pressure in patients with diabetes: Asian perspective. Yonsei Med J. 2016;57:1307–1311. doi: 10.3349/ymj.2016.57.6.1307. - DOI - PMC - PubMed
    1. Bays H, Gao P, Völker B, Mattheus M, Ruilope LM, Zhu D. Efficacy of single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg in patients with cardiovascular disease risk factors: A prospective subgroup analysis of a randomized, double-blind, and controlled trial. Int J Hypertens. 2013;2013:749830. doi: 10.1155/2013/749830. - DOI - PMC - PubMed
    1. Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, et al. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular Disease studies. J Hypertens. 2012;30:1004–1014. doi: 10.1097/HJH.0b013e3283522a51. - DOI - PubMed
    1. Takagi H, Umemoto T. Telmisartan increases adiponectin levels: A meta-analysis and meta-regression of randomized head-to-head trials. Int J Cardiol. 2012;155:448–451. doi: 10.1016/j.ijcard.2011.11.071. - DOI - PubMed
    1. Nilsson PM. Target blood pressure in diabetes patients with hypertension - what is the accumulated evidence in 2011? J Zhejiang Univ Sci B. 2011;12:611–623. doi: 10.1631/jzus.B1101001. - DOI - PMC - PubMed